2,4-Dinitrophenol (DNP)
2,4-Dinitrophenol (DNP) is a mitochondrial uncoupler that dramatically increases metabolic rate and produces rapid fat loss. It was briefly used as a diet drug in the 1930s before being withdrawn as unsafe. It has a narrow margin between an effective dose and a lethal one: overdose causes uncontrollable hyperthermia that is frequently fatal, and there is no antidote. It is genuinely dangerous.
01 Overview
DNP uncouples oxidative phosphorylation in mitochondria: it carries protons across the inner mitochondrial membrane, dissipating the proton gradient that normally drives ATP synthesis. The energy that would have been captured as ATP is released as heat instead, so the body burns substrate rapidly and inefficiently. This causes fast, dose-dependent fat loss but also a rise in body temperature that scales directly with dose.
The central danger is the narrow therapeutic-to-toxic margin combined with DNP's long half-life and cumulative action. As dose rises, heat production can exceed the body's ability to dissipate it, producing hyperthermia that becomes self-reinforcing and unresponsive to normal cooling. Severe overdose leads to tachycardia, profuse sweating, agitation, rigidity, multi-organ failure and death, sometimes within hours. There is no specific antidote; treatment is supportive cooling. Because potency varies between batches and effects accumulate over days, a dose that was tolerated can become lethal with continued use. These features are why DNP causes a disproportionate number of fatalities relative to how uncommon its use is.
02 Mechanism
Protonophore that uncouples oxidative phosphorylation by shuttling protons across the inner mitochondrial membrane, collapsing the proton-motive force. ATP synthesis falls and the released chemical energy is dissipated as heat, sharply raising metabolic rate and core temperature.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Historical low | 100–200 mg/day | Oral | Low end of historical/anecdotal use; even here hyperthermia risk exists and accumulates. |
| Anecdotal | 200–400 mg/day | Oral | Commonly cited anecdotal range; the margin to a dangerous cumulative dose is narrow and batch potency varies. |
| High-risk | 400–500 mg/day | Oral | Associated with severe hyperthermia and death; estimated lethal doses overlap this range. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Rapid fat lossMarked and rapid weight loss driven by greatly increased metabolic rate. | fast, dose-dependent | Observational | |
| Increased metabolic rateLarge increase in basal metabolic rate, the same mechanism that produces both fat loss and dangerous heat. | up to ~50% rise | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Fatal hyperthermiaHeat production can exceed the body's capacity to shed it, causing self-reinforcing hyperthermia that is frequently fatal and has no antidote; only supportive cooling exists. | Life-threatening | The defining risk | Clinical | |
| Tachycardia and cardiovascular collapseProfound tachycardia, sweating and haemodynamic instability progressing to collapse in toxicity. | Life-threatening | In overdose | Clinical | |
| CataractsHistorical use was associated with cataract formation. | Moderate | With repeated use | Observational |